Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also called...
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
Modified-Release Drug Delivery Systems: Overview01:19

Modified-Release Drug Delivery Systems: Overview

Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Adolescent social isolation and food restriction impairs feeding in female mice.

Neuroscience·2026
Same author

CHIO3: CHemotherapy combined with immune checkpoint inhibitor for operable stage IIIA/B (N2) Non-Small cell lung cancer (AFT-46).

Lung cancer (Amsterdam, Netherlands)·2026
Same author

Tandem electrostatic lens as a zoom system to achieve ultra-high magnification in microscope imaging mass spectrometry.

The Review of scientific instruments·2025
Same author

Primary prevention of cardiovascular disease in women.

Climacteric : the journal of the International Menopause Society·2024
Same author

Closing the gap: cardiovascular disease in women.

Climacteric : the journal of the International Menopause Society·2024
Same author

Development of novel projection-type imaging mass spectrometer.

The Review of scientific instruments·2021
Same journal

Mechanistic factors of cardiovascular diseases.

Minerva cardioangiologica·2020
Same journal

Robotic-assisted coronary artery bypass grafting: current knowledge and future perspectives.

Minerva cardioangiologica·2020
Same journal

Features of degenerative mitral valve prolapse in the North East of China: repair characteristics, and short-term follow-up results.

Minerva cardioangiologica·2020
Same journal

Myocardial revascularization in chronic coronary syndromes: does viability matter?

Minerva cardioangiologica·2020
Same journal

Extracorporeal membrane oxygenation for COVID-19: effective weapon or futile effort?

Minerva cardioangiologica·2020
Same journal

Heart and endurance sports: excesses are often unhealthy.

Minerva cardioangiologica·2020
See all related articles

Related Experiment Video

Updated: Jul 5, 2026

4D Printed Bifurcated Stents with Kirigami-Inspired Structures
06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

Future stent drug delivery systems.

A Caixeta1, A Abizaid, J Aoki

  • 1Heart Institute, Brasilia, DF, Brazil.

Minerva Cardioangiologica
|April 25, 2008
PubMed
Summary
This summary is machine-generated.

Drug-eluting stents (DES) reduce restenosis but can cause late thrombosis. Future DES designs aim to improve safety and endothelialization while maintaining efficacy for coronary artery disease treatment.

More Related Videos

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Related Experiment Videos

Last Updated: Jul 5, 2026

4D Printed Bifurcated Stents with Kirigami-Inspired Structures
06:52

4D Printed Bifurcated Stents with Kirigami-Inspired Structures

Published on: July 25, 2019

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers
12:30

Vascular Gene Transfer from Metallic Stent Surfaces Using Adenoviral Vectors Tethered through Hydrolysable Cross-linkers

Published on: August 12, 2014

Area of Science:

  • Cardiovascular medicine
  • Biomedical engineering
  • Interventional cardiology

Background:

  • Drug-eluting stents (DES) significantly reduce in-stent restenosis and repeat revascularization compared to bare metal stents (BMS).
  • Despite advances, some patients still experience in-stent restenosis after DES implantation.
  • Long-term safety concerns, including late-event thrombosis, persist with current DES technology.

Purpose of the Study:

  • To review novel generation drug-eluting stents (DES).
  • To discuss advancements in antiproliferative agents and stent materials.
  • To highlight future directions for DES design focusing on safety and efficacy.

Main Methods:

  • Literature review of recent advancements in drug-eluting stent technology.
  • Analysis of new antiproliferative agents and stent designs (polymeric and non-polymeric).
  • Discussion of strategies to mitigate thrombosis and promote endothelialization.

Main Results:

  • DES have proven effective in reducing restenosis across various patient and lesion subsets.
  • Challenges remain, including persistent restenosis in a small patient group and concerns over late thrombosis.
  • Novel DES generations are exploring new drugs and materials to address these limitations.

Conclusions:

  • Drug-eluting stents remain crucial for coronary artery disease treatment.
  • Future DES development must prioritize reducing thrombosis and enhancing endothelialization.
  • Innovations in antiproliferative agents and stent platforms are key to improving long-term DES safety and efficacy.